Dr Denis Lacombe, EORTC CEO, appointed stakeholder co-chair of ACT EU advisory group
24 May 2024
Dr Denis Lacombe, CEO of EORTC, has been appointed as the stakeholder co-chair of the ACT EU advisory group for a two-year mandate. This role offers new opportunities to collaborate more closely with regulatory bodies and other stakeholders, addressing daily challenges and developing new opportunities for conducting clinical research in Europe.
Additionally, Stephanie Kromar, Head of the Regulatory Department, and Stephane Lejeune, Head of the International Affairs and Policies Department, will represent EORTC on the ACT EU Advisory Group.
ACT EU is a unique initiative aimed at optimising the conduct of clinical research in Europe by addressing challenges arising from the rapidly evolving regulatory ecosystem and developing a specific scheme for academic clinical research.
ACT EU’s mission is to transform the initiation, design, and execution of clinical trials, promoting the development of high-quality, safe, and effective medicines. It also seeks to better integrate clinical research within the European health system. For more detailed information, visit Accelerating Clinical Trials in the EU (ACT EU) | European Medicines Agency (europa.eu).
Related News
EORTC research presented at ESMO 2026
22 Oct 2026
EORTC Quality of Life Group at ISOQOL 2026
15 Oct 2026
Pink October 2026: Advancing breast cancer research, together
7 Oct 2026
EORTC presents new results in neuro-oncology at EANO
28 Sep 2026
In Memoriam: Neil Aaronson, founding member of the EORTC Quality of Life Group
7 Sep 2026
New EORTC perspective calls for patient preferences to become a standard part of cancer trials for older adults
4 Sep 2026
New EORTC questionnaire sets a global standard for measuring quality of life in cancer survivors
25 Aug 2026
EORTC calls for a balanced and feasible European Health Data Space (EHDS)
8 Jul 2026
Professor Benjamin Besse becomes President of EORTC
26 Jun 2026
CCTG, EORTC and UK3CR welcome G7 commitment to accelerate global progress against cancer
24 Jun 2026
